Physician profile
Amber M Jobe
NPI 1700261161
$37,312.96
in general payments reported to CMS, 2019-2025
56 companies · $11K in 2025
The $11K reported for 2025 was more than what 94% of Neuroscience (Registered Nurse) providers received nationally (typical 2025 total: $185).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,184 · 2022: $11K · 2023: $6,919 · 2024: $3,751 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,480 · Honoraria: $2,000 · Travel and Lodging: $749 · Consulting Fee: $450 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,958.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,480.00 |
| Honoraria | $2,000.00 |
| Travel and Lodging | $749.07 |
| Consulting Fee | $450.00 |
| Education | $195.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,183.01 | 2021-2025 | |
| Catalyst Pharmaceuticals, INC. | $3,054.44 | 2023 | Firdapse |
| Genentech USA, INC. | $2,318.36 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| Emd Serono, INC. | $1,655.10 | 2021-2023 | Mavenclad |
| Biogen, INC. | $1,580.12 | 2021-2025 | Tysabri, Vumerity, Skyclarys |
| Teva Pharmaceuticals USA, INC. | $1,400.76 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,355.94 | 2021-2024 | Xarelto, Ponvory |
| Horizon Therapeutics Plc | $1,303.65 | 2021-2023 | Uplizna |
| Genzyme Corporation | $1,272.21 | 2021-2025 | |
| Amgen INC. | $1,147.28 | 2021-2025 | Uplizna, Repatha |
| Janssen Scientific Affairs, LLC | $1,040.00 | 2022 | |
| Pfizer INC. | $938.15 | 2023-2025 | |
| Celgene Corporation | $758.10 | 2021-2025 | Zeposia |
| Lundbeck LLC | $754.01 | 2021-2025 | Vyepti |
| Lilly USA, LLC | $696.94 | 2021-2025 | Emgality, Kisunla, Amyvid |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $649.47 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $636.38 | 2021-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $532.91 | 2021-2025 | Koselugo, Ultomiris |
| Eisai INC. | $437.95 | 2021-2025 | |
| Axsome Therapeutics, INC. | $419.86 | 2024-2025 | Symbravo, Auvelity, Sunosi |
| Biohaven Pharmaceuticals, INC. | $387.56 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $373.63 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $298.68 | 2022-2025 | Purified Cortrophin Gel |
| Argenx US, INC. | $286.87 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Allergan, INC. | $280.24 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $259.31 | 2022 | |
| Kyowa Kirin, INC. | $208.38 | 2021-2022 | |
| Neurelis, INC. | $202.72 | 2024-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $189.79 | 2022-2023 | |
| Currax Pharmaceuticals LLC | $178.78 | 2025 | Onzetra Xsail, Contrave |
| Vanda Pharmaceuticals INC. | $174.55 | 2024-2025 | Ponvory |
| Amneal Pharmaceuticals LLC | $140.90 | 2025 | Ongentys, Crexont |
| Ipsen Biopharmaceuticals, INC | $108.48 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $108.18 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $86.81 | 2024-2025 | |
| Upsher-Smith Laboratories LLC | $85.06 | 2021-2022 | |
| Csl Behring | $79.97 | 2025 | Hizentra |
| Banner Life Sciences, LLC | $72.34 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $71.54 | 2021 | |
| Springworks Therapeutics, INC. | $67.73 | 2025 | Gomekli |
| Alnylam Pharmaceuticals INC. | $62.09 | 2024-2025 | Amvuttra |
| Takeda Pharmaceuticals U.S.A., INC. | $47.04 | 2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $43.03 | 2022 | |
| Livanova USA, INC. | $41.63 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Acadia Pharmaceuticals INC | $40.04 | 2025 | Nuplazid |
| Novocure INC. | $38.31 | 2025 | Optune Gio |
| Sunovion Pharmaceuticals INC. | $37.90 | 2022 | |
| Insightec,INC | $32.23 | 2025 | Exablate |
| Avion Pharmaceuticals | $31.53 | 2022 | |
| Abiomed | $31.35 | 2024 | Impella |
| Sk Life Science, INC. | $30.15 | 2025 | |
| Azurity Pharmaceuticals, INC. | $18.99 | 2025 | Zonisade |
| Grifols USA, LLC | $16.96 | 2021 | |
| Life Molecular Imaging Ltd | $16.64 | 2023 | Neuraceq |
| Ultragenyx Pharmaceutical INC. | $15.00 | 2025 | Dojolvi |
| Impel Pharmaceuticals LLC | $13.91 | 2024 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Jobe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.